[Adalimumab for early rheumatoid arthritis - Chances and risks: Initial analyses of the OPTIMA study]
- PMID: 23685856
- DOI: 10.1007/s00393-013-1184-z
[Adalimumab for early rheumatoid arthritis - Chances and risks: Initial analyses of the OPTIMA study]
Comment on
-
Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study.Ann Rheum Dis. 2013 Jan;72(1):64-71. doi: 10.1136/annrheumdis-2011-201247. Epub 2012 May 5. Ann Rheum Dis. 2013. PMID: 22562973 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical